PRLD earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -3.70. Updated 2026-07-23.
Prelude Therapeutics (PRLD) Research Hub
Prelude Therapeutics (PRLD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.59 USD (-9.82%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.70, market cap 0.22B. This hub links to the full technical, earnings and options research available for PRLD.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.59 USD (-9.82%) |
| 52-week range | 3.77 USD – 6.82 USD |
| Trend regime | Range |
| 14-day RSI | 46.3 (Neutral) |
| Trailing P/E | -3.70 |
| Market cap | 0.22B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for PRLD
Covered Call on PRLD: how it works, illustrative setup around the real 4.59 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PRLD: how it works, illustrative setup around the real 4.59 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PRLD: how it works, illustrative setup around the real 4.59 USD price, max profit/loss, breakeven and when to use it. Educational.
PRLD technical analysis: range, last 4.59 USD, RSI 46.3, 52w range 3.77 USD–6.82 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PRLD in?
Prelude Therapeutics (PRLD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PRLD in an uptrend or downtrend?
As of 2026-09-11, PRLD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PRLD's trailing P/E ratio?
PRLD's trailing P/E is -3.70, with a market cap of 0.22B. See the earnings research page for full valuation detail.
When does PRLD next report earnings?
PRLD is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.2225 USD.